CPTX-2506

CPTX-2506 is an investigational in vivo CAR-T cell therapy designed for delivery using targeted lipid nanoparticles (tLNPs). This therapy is being developed by Capstan Therapeutics. The tLNPs act as vehicles to deliver genetic material in vivo, enabling *direct reprogramming of a patient's own T cells* inside the body to express a chimeric antigen receptor (CAR), potentially bypassing the need for complex ex vivo cell engineering processes typical of traditional CAR-T therapies. The current clinical focus is on immunotherapy, likely targeting oncology or severe autoimmune indications, but precise details about its target antigens, full mechanism of action, or specific indications under trial are not yet public[7].